Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.
about
An individualized prognostic signature and multi‑omics distinction for early stage hepatocellular carcinoma patients with surgical resectionPrimary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression.Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.The effect of information on preferences for treatments of metastatic renal cell carcinoma.Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.
P2860
Q37269227-022C82D9-99D3-47E1-ACC4-C69BFB6E2BCAQ37657236-4633A682-2412-44CA-8003-7EC144B8C052Q38259501-83E835B0-4E06-4BCE-83A9-E780FC3BCB2CQ39233456-03BE1BB9-98F1-4DFC-9B96-1EEC41804F08Q40955279-435B751A-182E-4A4A-8AE7-F7F4B9D72694Q42921489-C63D3F3E-CA12-4A36-9902-B69006477E4FQ47269814-C9A52FF0-8DA4-40EB-BA73-93E2AF75CE57Q52650529-D5146E96-AE4D-4B56-837D-E57CC33BF022Q53136887-D6E01A53-9B25-4FDA-B579-1B01FC3922E8Q53717818-02D3D973-081E-4BD2-AB47-5A8ACE5FBFBD
P2860
Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Association between treatment ...... tastatic renal cell carcinoma.
@en
type
label
Association between treatment ...... tastatic renal cell carcinoma.
@en
prefLabel
Association between treatment ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P356
P1476
Association between treatment ...... tastatic renal cell carcinoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2012.367
P407
P577
2012-08-30T00:00:00Z
P5875
P6179
1034198532